Top Markets
#1 BOOK OF MEME BOOK OF MEME +29.78%
#2 Geodnet Geodnet +26.04%
#3 The Black Bull The Black Bull +25.24%
#4 XPIN Network XPIN Network +23.44%
#5 EXOD EXOD +22.08%
#6 Ore Ore +21.41%
#7 Verus Coin Verus Coin +20.44%
#8 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +20.08%
#9 Neiro Neiro +19.97%
#10 Bitcoin Cash Bitcoin Cash +19.67%
Coin of the day
BOOK OF MEME BOOK OF MEME
Settings
Language
ENGLISH
Currency
USD
Theme
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rank in Stocks #25182
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Share Price
$1.95
Last synced: 2022-07-29
Market Cap
$52.48M
Change (1 day)
2.63%
Change (1 year)
0.00%
Country
US
Trade Cortexyme, Inc. (CRTX)

Category

Healthcare
Revenue for Cortexyme, Inc. (CRTX)
Revenue in Aug 2026 TTM: 0
According to Cortexyme, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cortexyme, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US